{"slideshow_credits": null, "snippet": "A partnership between the Drug Enforcement Administration and drug makers is behind a shortage that is prompting a wave of complaints to the Food and Drug Administration.", "abstract": "Shortages of medicines used to treat attention deficit hyperactivity disorder have created a rare open dispute between the Food and Drug Administration and the Drug Enforcement Administration; FDA says that the shortages are a result of overly strict quotas set by the DEA, which, for its part, questions whether there really are shortages or whether manufacturers are simply choosing to make more expensive pills than generics, creating supply and demand imbalances.", "section_name": "Health", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gardiner", "role": "reported", "lastname": "HARRIS", "rank": 1, "organization": ""}], "original": "By GARDINER HARRIS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/01/01/health/policy/fda-is-finding-attention-drugs-in-short-supply.html", "lead_paragraph": "A partnership between the Drug Enforcement Administration and drug makers is behind a shortage that is prompting a wave of complaints to the Food and Drug Administration.", "headline": {"main": "F.D.A. Finds Short Supply of Attention Deficit Drugs", "print_headline": "F.D.A. Is Finding Attention Drugs in Short Supply"}, "_id": "5404be0b38f0d8119d157524", "word_count": "1103", "multimedia": [{"height": 383, "url": "images/2012/01/01/us/JP-DRUG/JP-DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2012/01/01/us/JP-DRUG/JP-DRUG-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "383"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2012/01/01/us/JP-DRUG/JP-DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2012/01/01/us/JP-DRUG/JP-DRUG-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2012-01-01T00:00:00Z", "source": "The New York Times", "news_desk": "National", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Drug Enforcement Administration", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Attention Deficit Hyperactivity Disorder", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Shortages", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Ritalin (Drug)", "name": "subject", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "Money & Policy", "type_of_material": "News"}